We conducted a review of the literature to identify the clinical benefits of pelvic lymph node dissection (PLND) during radical prostatectomy for clinically localized prostate cancer. The most recent guidelines recommend PLND, particularly extended PLND, during radical prostatectomy for localized prostate cancer. PLND is undoubtedly the most accurate method for nodal staging, and most patients, particularly those with high-risk cancer, are likely to undergo PLND during radical prostatectomy. Although many retrospective studies have assessed oncologic outcomes after PLND, its therapeutic benefit remains controversial. Patients with positive node(s) often have other more common unfavorable prognostic factors, such as seminal vesicle invasion, extra-prostatic extension, and positive surgical margins. Oncologic outcomes in patients who have not undergone PLND and those who have undergone PLND are almost identical. If an effective standard adjuvant therapy after prostatectomy is defined, the nodal status may be important and valuable. However, adjuvant treatment strategies for patients with a positive node have not been identified thus far. Therefore, determining the nodal status at surgery may not provide therapeutic benefit. PLND requires additional surgical time and is associated with several complications. Therefore, the indication for PLND should be considered carefully until well-designed prospective randomized trials establish high-quality clinical evidence.

Keywords:
Lymph node prostate cancer, Prostatectomy, Prognosis, Complication
1.
Dominguez-Escrig JL, Peyronnet B, Seisen T, Bruins HM, Yuan CY, Babjuk M, et al. Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer.
Eur Urol Focus
. 2017 Nov 17. pii: S2405-4569(17)30236-5.
2.
Bruins HM, Veskimae E, Hernandez V, Imamura M, Neuberger MM, Dahm P, et al. The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review.
Eur Urol
. 2014 Dec;66(6):1065–77.
3.
Yadav K. Retroperitoneal lymph node dissection: an update in testicular malignancies.
Clin Transl Oncol
. 2017 Jul;19(7):793–8.
4.
Ristau BT, Manola J, Haas NB, Heng DY, Messing EM, Wood CG, et al. Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial.
J Urol
. 2018 Jan;199(1):53–9.
5.
Suardi N, Larcher A, Haese A, Ficarra V, Govorov A, Buffi NM, et al.; EAU Young Academic Urologists–Robotic Section. Indication for and extension of pelvic lymph node dissection during robot-assisted radical prostatectomy: an analysis of five European institutions.
Eur Urol
. 2014 Oct;66(4):635–43.
6.
Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
Eur Urol
. 2017 Apr;71(4):618–29.
7.
Fossati N, Willemse PM, Van den Broeck T, van den Bergh RC, Yuan CY, Briers E, et al. The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review.
Eur Urol
. 2017 Jul;72(1):84–109.
8.
Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, et al. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options.
J Urol
. 2018 Apr;199(4):990–7.
9.
Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy.
JAMA
. 1999 May;281(17):1591–7.
10.
Boorjian SA, Thompson RH, Tollefson MK, Rangel LJ, Bergstralh EJ, Blute ML, et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence.
Eur Urol
. 2011 Jun;59(6):893–9.
11.
Moschini M, Sharma V, Zattoni F, Quevedo JF, Davis BJ, Kwon E, et al. Natural History of Clinical Recurrence Patterns of Lymph Node-Positive Prostate Cancer After Radical Prostatectomy.
Eur Urol
. 2016 Jan;69(1):135–42.
12.
Gofrit ON, Zorn KC, Steinberg GD, Zagaja GP, Shalhav AL; Gofrit ON1. Zorn KC, Steinberg GD, Zagaja GP, Shalhav AL. The Will Rogers phenomenon in urological oncology.
J Urol
. 2008;179(1):28–33.
13.
Munbauhal G, Seisen T, Gomez FD, Peyronnet B, Cussenot O, Shariat SF, et al. Current perspectives of sentinel lymph node dissection at the time of radical surgery for prostate cancer.
Cancer Treat Rev
. 2016 Nov;50:228–39.
14.
Chatterjee A, Serniak N, Czerniecki BJ. Sentinel lymph node biopsy in breast cancer: a work in progress.
Cancer J
. 2015 Jan-Feb;21(1):7–10.
15.
Van den Bergh L, Joniau S, Haustermans K, Deroose CM, Isebaert S, Oyen R, et al. Reliability of sentinel node procedure for lymph node staging in prostate cancer patients at high risk for lymph node involvement.
Acta Oncol
. 2015 Jun;54(6):896–902.
16.
Mattei A, Fuechsel FG, Bhatta Dhar N, Warncke SH, Thalmann GN, Krause T, et al. The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study.
Eur Urol
. 2008 Jan;53(1):118–25.
17.
Joniau S, Van den Bergh L, Lerut E, Deroose CM, Haustermans K, Oyen R, et al. Mapping of pelvic lymph node metastases in prostate cancer.
Eur Urol
. 2013 Mar;63(3):450–8.
18.
Fergany A, Kupelian PA, Levin HS, Zippe CD, Reddy C, Klein EA. No difference in biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients.
Urology
. 2000 Jul;56(1):92–5.
19.
Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis.
J Urol
. 2002 Apr;167(4):1681–6.
20.
Bader P, Burkhard FC, Markwalder R, Studer UE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?
J Urol
. 2003 Mar;169(3):849–54.
21.
Allaf ME, Palapattu GS, Trock BJ, Carter HB, Walsh PC. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer.
J Urol
. 2004 Nov;172(5 Pt 1):1840–4.
22.
Bhatta-Dhar N, Reuther AM, Zippe C, Klein EA. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.
Urology
. 2004 Mar;63(3):528–31.
23.
Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE. Is pelvic lymph node dissection necessary in patients with a serum PSA[{LT}]10ng/ml undergoing radical prostatectomy for prostate cancer?
Eur Urol
. 2006 Aug;50(2):272–9.
24.
Berglund RK, Sadetsky N, DuChane J, Carroll PR, Klein EA. Limited pelvic lymph node dissection at the time of radical prostatectomy does not affect 5-year failure rates for low, intermediate and high risk prostate cancer: results from CaPSURE.
J Urol
. 2007 Feb;177(2):526–9.
25.
Schiavina R, Manferrari F, Garofalo M, Bertaccini A, Vagnoni V, Guidi M, et al. The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer.
BJU Int
. 2011 Oct;108(8):1262–8.
26.
Ku JH, Jeong CW, Park YH, Cho MC, Kwak C, Kim HH. Biochemical recurrence after radical prostatectomy with or without pelvic lymphadenectomy in Korean men with high-risk prostate cancer.
Jpn J Clin Oncol
. 2011 May;41(5):656–62.
27.
Dorin RP, Daneshmand S, Lassoff MA, Cai J, Skinner DG, Lieskovsky G. Long-term outcomes of open radical retropubic prostatectomy for clinically localized prostate cancer in the prostate-specific antigen era.
Urology
. 2012 Mar;79(3):626–31.
28.
Daimon T, Miyajima A, Maeda T, Hattori S, Yasumizu Y, Hasegawa M, et al. Does pelvic lymph node dissection improve the biochemical relapse-free survival in low-risk prostate cancer patients treated by laparoscopic radical prostatectomy?
J Endourol
. 2012 Sep;26(9):1199–202.
29.
Jung JH, Seo JW, Lim MS, Lee JW, Chung BH, Hong SJ, et al. Extended pelvic lymph node dissection including internal iliac packet should be performed during robot-assisted laparoscopic radical prostatectomy for high-risk prostate cancer.
J Laparoendosc Adv Surg Tech A
. 2012 Oct;22(8):785–90.
30.
Briganti A, Larcher A, Abdollah F, Capitanio U, Gallina A, Suardi N, et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores.
Eur Urol
. 2012 Mar;61(3):480–7.
31.
van der Poel HG, Tillier C, de Blok W, van Muilekom E. Extended nodal dissection reduces sexual function recovery after robot-assisted laparoscopic prostatectomy.
J Endourol
. 2012 Sep;26(9):1192–8.
32.
Sagalovich D, Calaway A, Srivastava A, Sooriakumaran P, Tewari AK. Assessment of required nodal yield in a high risk cohort undergoing extended pelvic lymphadenectomy in robotic-assisted radical prostatectomy and its impact on functional outcomes.
BJU Int
. 2013 Jan;111(1):85–94.
33.
Mitsuzuka K, Koie T, Narita S, Kaiho Y, Yoneyama T, Kawamura S, et al.; Mitsuzuka K1. Koie T, Narita S, Kaiho Y, Yoneyama T, Kawamura S, Tochigi T, Ohyama C, Habuchi T, Arai Y. Is pelvic lymph node dissection required at radical prostatectomy for low-risk prostate cancer?
Int J Urol
. 2013;20(11):1092–6.
34.
Kim KH, Lim SK, Kim HY, Shin TY, Lee JY, Choi YD, et al. Extended vs standard lymph node dissection in robot-assisted radical prostatectomy for intermediate- or high-risk prostate cancer: a propensity-score-matching analysis.
BJU Int
. 2013 Jul;112(2):216–23.
35.
Yuh BE, Ruel NH, Mejia R, Novara G, Wilson TG. Standardized comparison of robot-assisted limited and extended pelvic lymphadenectomy for prostate cancer.
BJU Int
. 2013 Jul;112(1):81–8.
36.
Moris L, Van den Broeck T, Tosco L, Van Baelen A, Gontero P, Karnes RJ, et al. Impact of Lymph Node Burden on Survival of High-risk Prostate Cancer Patients Following Radical Prostatectomy and Pelvic Lymph Node Dissection.
Front Surg
. 2016 Dec;3:65.
37.
Furubayashi N, Negishi T, Iwai H, Nagase K, Taguchi K, Shimokawa M, et al. Determination of adequate pelvic lymph node dissection range for Japanese males undergoing radical prostatectomy.
Mol Clin Oncol
. 2017 May;6(5):775–81.
38.
Albisinni S, Aoun F, LE Dinh D, Zanaty M, Hawaux E, Peltier A, et al. Comparing conventional laparoscopic to robotic-assisted extended pelvic lymph node dissection in men with intermediate and high-risk prostate cancer: a matched-pair analysis.
Minerva Urol Nefrol
. 2017 Feb;69(1):101–7.
39.
Gandaglia G, De Lorenzis E, Novara G, Fossati N, De Groote R, Dovey Z, et al. Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection in Patients with Locally-advanced Prostate Cancer.
Eur Urol
. 2017 Feb;71(2):249–56.
40.
Mistretta FA, Boeri L, Grasso AA, Lo Russo V, Albo G, DE Lorenzis E, et al. Extended versus standard pelvic lymphadenectomy during robot-assisted radical prostatectomy: the role of extended template as an independent predictor of lymph node invasion with comparable morbidity burden.
Minerva Urol Nefrol
. 2017 Oct;69(5):475–85.
41.
Porcaro AB, De Luyk N, Corsi P, Sebben M, Tafuri A, Processali T, et al. Clinical Factors Predicting Bilateral Lymph Node Invasion in High-Risk Prostate Cancer.
Urol Int
. 2017;99(4):392–9.
42.
Maderthaner L, Furrer MA, Studer UE, Burkhard FC, Thalmann GN, Nguyen DP. More extended lymph node dissection template at radical prostatectomy detects metastases in the common iliac region and in the fossa of Marcille.
BJU Int
. 2018 May;121(5):725–31.
43.
Chenam A, Ruel N, Pal S, Barlog J, Lau C, Wilson T, et al. Biochemical recurrence after robot-assisted extended pelvic lymphadenectomy for prostate cancer.
Can J Urol
. 2018 Jun;25(3):9340–8.
44.
Roscigno M, Nicolai M, La Croce G, Pellucchi F, Scarcello M, Saccà A, et al. Difference in Frequency and Distribution of Nodal Metastases Between Intermediate and High Risk Prostate Cancer Patients: Results of a Superextended Pelvic Lymph Node Dissection.
Front Surg
. 2018 Sep;5:52.
45.
Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, et al.; Eastern Cooperative Oncology Group study EST 3886. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.
Lancet Oncol
. 2006 Jun;7(6):472–9.
46.
Abdollah F, Karnes RJ, Suardi N, Cozzarini C, Gandaglia G, Fossati N, et al. Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer.
J Clin Oncol
. 2014 Dec;32(35):3939–47.
47.
Touijer KA, Karnes RJ, Passoni N, Sjoberg DD, Assel M, Fossati N, et al. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.
Eur Urol
. 2018 Jun;73(6):890–6.
48.
Touijer KA, Mazzola CR, Sjoberg DD, Scardino PT, Eastham JA. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy.
Eur Urol
. 2014 Jan;65(1):20–5.
49.
Boström PJ, Bjartell AS, Catto JW, Eggener SE, Lilja H, Loeb S, et al. Genomic Predictors of Outcome in Prostate Cancer.
Eur Urol
. 2015 Dec;68(6):1033–44.
50.
Kim SJ, Lee SW, Ha HK. Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Meta-Analysis.
Urol Int
. 2018;28:1–10.
51.
Weight CJ, Reuther AM, Gunn PW, Zippe CR, Dhar NB, Klein EA. Limited pelvic lymph node dissection does not improve biochemical relapse-free survival at 10 years after radical prostatectomy in patients with low-risk prostate cancer.
Urology
. 2008 Jan;71(1):141–5.
52.
Porter CR, Suardi N, Capitanio U, Hutterer GC, Kodama K, Gibbons RP, et al. A nomogram predicting prostate cancer-specific mortality after radical prostatectomy.
Urol Int
. 2010;84(2):132–40.
53.
Liss MA, Palazzi K, Stroup SP, Jabaji R, Raheem OA, Kane CJ. Outcomes and complications of pelvic lymph node dissection during robotic-assisted radical prostatectomy.
World J Urol
. 2013 Jun;31(3):481–8.
54.
Gandaglia G, Ploussard G, Isbarn H, Suardi N, De Visschere PJ, Futterer JJ, et al.; Prostate Cancer Working Group of Young Academic Urologists Working Party of European Association of Urology. What is the optimal definition of misclassification in patients with very low-risk prostate cancer eligible for active surveillance? Results from a multi-institutional series [Karl A, Buchner A, Tympner C, Kirchner T, Ganswindt U, Belka C, et al.].
Urol Oncol
. 2015 Apr;33(4):164.e1–9.
55.
Karl A, Buchner A, Tympner C, Kirchner T, Ganswindt U, Belka C, et al. Risk and timing of biochemical recurrence in pT3aN0/Nx prostate cancer with positive surgical margin - A multicenter study.
Radiother Oncol
. 2015 Jul;116(1):119–24.
56.
Koo KC, Tuliao P, Komninos C, Choi YD, Chung BH, Hong SJ, et al. Prognostic impact of time to undetectable prostate-specific antigen in patients with positive surgical margins following radical prostatectomy.
Ann Surg Oncol
. 2015 Feb;22(2):693–700.
57.
Boehm K, Beyer B, Tennstedt P, Schiffmann J, Budaeus L, Haese A, et al. No impact of blood transfusion on oncological outcome after radical prostatectomy in patients with prostate cancer.
World J Urol
. 2015 Jun;33(6):801–6.
58.
Bivalacqua TJ, Pierorazio PM, Gorin MA, Allaf ME, Carter HB, Walsh PC. Anatomic extent of pelvic lymph node dissection: impact on long-term cancer-specific outcomes in men with positive lymph nodes at time of radical prostatectomy.
Urology
. 2013 Sep;82(3):653–8.
59.
Hatzichristodoulou G, Wagenpfeil S, Wagenpfeil G, Maurer T, Horn T, Herkommer K, et al. Extended versus limited pelvic lymph node dissection during bilateral nerve-sparing radical prostatectomy and its effect on continence and erectile function recovery: long-term results and trifecta rates of a comparative analysis.
World J Urol
. 2016 Jun;34(6):811–20.
60.
Choo MS, Kim M, Ku JH, Kwak C, Kim HH, Jeong CW. Extended versus Standard Pelvic Lymph Node Dissection in Radical Prostatectomy on Oncological and Functional Outcomes: A Systematic Review and Meta-Analysis.
Ann Surg Oncol
. 2017 Jul;24(7):2047–54.
61.
Masterson TA, Bianco FJ Jr, Vickers AJ, DiBlasio CJ, Fearn PA, Rabbani F, et al. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer.
J Urol
. 2006 Apr;175(4):1320–4.
62.
Abdollah F, Gandaglia G, Suardi N, Capitanio U, Salonia A, Nini A, et al. More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer.
Eur Urol
. 2015 Feb;67(2):212–9.
63.
Joslyn SA, Konety BR. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer.
Urology
. 2006 Jul;68(1):121–5.
64.
Fossati N, Parker WP, Karnes RJ, Colicchia M, Bossi A, Seisen T, et al. More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis.
Eur Urol
. 2018 Aug;74(2):134–7.
65.
Murphy AM, Berkman DS, Desai M, Benson MC, McKiernan JM, Badani KK. The number of negative pelvic lymph nodes removed does not affect the risk of biochemical failure after radical prostatectomy.
BJU Int
. 2010 Jan;105(2):176–9.
66.
DiMarco DS, Zincke H, Sebo TJ, Slezak J, Bergstralh EJ, Blute ML. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
J Urol
. 2005 Apr;173(4):1121–5.
67.
Pierorazio PM, Gorin MA, Ross AE, Feng Z, Trock BJ, Schaeffer EM, et al. Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30-year experience.
Prostate
. 2013;73:1673–80.
68.
Preisser F, Bandini M, Marchioni M, Nazzani S, Tian Z, Pompe RS, et al. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion.
Prostate
. 2018 May;78(6):469–75.
69.
Abdollah F, Schmitges J, Sun M, Tian Z, Briganti A, Shariat SF, et al. A critical assessment of the value of lymph node dissection at radical prostatectomy: A population-based study.
Prostate
. 2011 Oct;71(14):1587–94.
70.
Miyake H, Hara I, Kurahashi T, Inoue TA, Eto H, Fujisawa M. Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase-PCR.
Clin Cancer Res
. 2007 Feb;13(4):1192–7.
71.
Choi SB, Han HJ, Park P, Kim WB, Song TJ, Choi SY. Systematic review of the clinical significance of lymph node micrometastases of pancreatic adenocarcinoma following surgical resection.
Pancreatology
. 2017 May - Jun;17(3):342–9.
72.
Hong KD, Um JW, Min BW, Ji WB, Choi JW, Kim YS. Lymph Node Micrometastasis Cannot Be Considered as Positive Lymph Node in Nonmetastatic Colorectal Cancer.
Am Surg
. 2017 Feb;83(2):127–33.
73.
Zhou Y, Zhang GJ, Wang J, Zheng KY, Fu W. Current status of lymph node micrometastasis in gastric cancer.
Oncotarget
. 2017 Apr;8(31):51963–9.
74.
Beauval JB, Roumiguié M, Filleron T, Benoit T, de la Taille A, Malavaud B, et al. Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer.
BMC Urol
. 2016 Jun;16(1):26.
75.
Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, et al. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
BJU Int
. 2011 Jun;107(11):1748–54.
76.
Palapattu GS, Allaf ME, Trock BJ, Epstein JI, Walsh PC. Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup.
J Urol
. 2004 Nov;172(5 Pt 1):1860–4.
77.
Daneshmand S, Quek ML, Stein JP, Lieskovsky G, Cai J, Pinski J, et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results.
J Urol
. 2004 Dec;172(6 Pt 1):2252–5.
78.
Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
J Urol
. 2007 Sep;178(3 Pt 1):864–70.
79.
Dorin RP, Lieskovsky G, Fairey AS, Cai J, Daneshmand S. Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era.
Urol Oncol
. 2013 Nov;31(8):1441–7.
80.
Mandel P, Kriegmair MC, Bogdan K, Boehm K, Budäus L, Graefen M, et al. Association between Lymph Node Counts and Oncological Outcomes in Lymph Node Positive Prostate Cancer.
Eur Urol Focus
. 2017 Apr;3(2-3):248–55.
81.
Badani KK, Reddy BN, Moskowitz EJ, -Paulucci DJ, Beksac AT, Martini A, et al. Lymph node yield during radical -prostatectomy does not impact rate of -biochemical recurrence in patients with seminal vesicle invasion and node-negative disease.
Urol Oncol
. 2018 Jun;36(6):310.e1–6.
82.
Jackson WC, Desai NB, Abugharib AE, -Tumati V, Dess RT, Lee JY, et al. Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study.
BJU Int
. 2017 Sep;120(3):351–7.
83.
Köllermann J, Weikert S, Schostak M, Kempkensteffen C, Kleinschmidt K, Rau T, et al. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
J Clin Oncol
. 2008 Oct;26(30):4928–33.
84.
Song W, Park JH, Jeon HG, Jeong BC, Seo SI, Jeon SS, et al. Comparison of Oncologic Outcomes and Complications According to Surgical Approach to Radical Prostatectomy: Special Focus on the Perineal Approach.
Clin Genitourin Cancer
. 2017 Aug;15(4):e645–52.
85.
Syed YA, Patel-Yadav AK, Rivers C, Singh AK. Stereotactic radiotherapy for prostate cancer: A review and future directions.
World J Clin Oncol
. 2017 Oct;8(5):389–97.
86.
Yahara K, Ohguri T, Yamaguchi S, Imada H, Narisada H, Ota S, et al. Definitive radiotherapy plus regional hyperthermia for high-risk and very high-risk prostate carcinoma: thermal parameters correlated with biochemical relapse-free survival.
Int J Hyperthermia
. 2015;31(6):600–8.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.